<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Neurology</journal-id><journal-id journal-id-type="iso-abbrev">Neurology</journal-id><journal-id journal-id-type="hwp">neurology</journal-id><journal-id journal-id-type="publisher-id">neur</journal-id><journal-id journal-id-type="pmc">neurology</journal-id><journal-id journal-id-type="publisher-id">NEUROLOGY</journal-id><journal-title-group><journal-title>Neurology</journal-title></journal-title-group><issn pub-type="ppub">0028-3878</issn><issn pub-type="epub">1526-632X</issn><publisher><publisher-name>Lippincott Williams &#x00026; Wilkins</publisher-name><publisher-loc>Hagerstown, MD</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29374102</article-id><article-id pub-id-type="pmc">5818163</article-id><article-id pub-id-type="publisher-id">NEUROLOGY2017834184</article-id><article-id pub-id-type="doi">10.1212/WNL.0000000000004997</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>2</subject><subject>6</subject><subject>12</subject><subject>17</subject></subj-group><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Early time course of major bleeding on antiplatelet therapy after TIA or ischemic stroke</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Hilkens</surname><given-names>Nina A.</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>Dutch Heart Foundation, grant number 2013T128</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Algra</surname><given-names>Ale</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>I am member of two data safety monitoring boards: ECST-2 (PI prof MM Brown, London, UK) and TRIDENT(PI prof C. Anderson, Sydney. Both trials are investigator initiated trials not sponsored by industry.</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Stroke, member editorial board, since 2010. Cochrane Stroke Group, member editorial board, since 2004.</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Kappelle</surname><given-names>L. Jaap</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>Served on a scientific advisory board for Boehringer Ingelheim, Bayer Health Care and Bristol Meyers Squibb</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>Profit entity: I received travel and speaker honoraria from Boehringer Ingelheim</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Bath</surname><given-names>Philip M.</given-names></name><degrees>FRCP, DSc</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>1. Athersys 2. Covidien 3. Diamedica 4. Nestle 5. Phagenesis Ltd 6. ReNeuron Ltd</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>1. Athersys, honorarium 2. Covidien, honorarium 3. Nestle, honorarium 4. Phagenesis Ltd, honorarium 5. ReNeuron Ltd, honorarium</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>1. Athersys, honorarium 2. Covidien, honorarium 3. Nestle, honorarium 4. Phagenesis Ltd, honorarium 5. ReNeuron Ltd, honorarium</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>1. European Journal Stroke 2. International Journal of Stroke, member editorial advisory board, ongoing</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>Unpaid member of board: 1. Platelet Solutions Ltd</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>1. Athersys 2. Covidien 3. Diamedica 4. Nestle 5. Phagenesis Ltd 6. ReNeuron Ltd</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>1. Medical Research Council, funded ENOS trial, 2005-14, Chief Investigator 2. National Institute of Health Research Health Technology Assessment Programme, funds TARDIS trial, 2009-17, Chief Investigator</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>1. British Heart Foundation, Chief Investigator</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>1. Diamedica 2. Platelet Solutions</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Csiba</surname><given-names>L&#x000e1;szl&#x000f3;</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>1. Rocket AF international pharma trial, steering committe 2. Stroke Prevention in Atrial Fibrillation Alliance non-profit</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>Cony covers the travel cost (NOT honoraria) to the annual meeting</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>assoc. editor of Frontiers in Stroke member of editorial board: Intern J Stroke, Ideg. Szle, LAM,</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>speaker of the European Master Course on Stroke (non- profit)</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Rothwell</surname><given-names>Peter M.</given-names></name><degrees>MD, PhD, FRCP, FMedSci</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>Bayer - Executive Committee of ARRIVE Trial - 2006 onwards Servier - Executive Committee of PERFORM trial - 2005 -2010 Pfizer - IDMC if Rocket-AF Trial - 2006 - 2009 Biotronic - Executive Committee of device trial - 2005 - 2011</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>I don't keep a record. Certainly had travel expenses paid by Sanofi-Aventis, Servier, Astra-Zeneca and Bayer in past. However, nothing relevant to this manuscript.</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Editorial Board - Lancet Neurology, International Journal of Stroke</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Greving</surname><given-names>Jacoba P.</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>1. data safety monitoring board for a non-industry sponsored trial</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>1. Rudolf Magnus Young Talent Fellowship, 2013 2. Dutch Heart Foundation (grant number 2013T128), 2013</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><on-behalf-of>On behalf of the CAT Collaboration</on-behalf-of><aff>From the Julius Center for Health Sciences and Primary Care (N.A.H., A.A., J.P.G.) and Department of Neurology and Neurosurgery (A.A., L.J.K.), Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht University, the Netherlands; Stroke Trials Unit (P.M.B.), Division of Clinical Neuroscience, University of Nottingham, UK; Department of Neurology (L.C.), University of Debrecen Medical and Health Science Center, Hungary; and Stroke Prevention Research Unit (P.M.R.), Nuffield Department of Clinical Neurosciences, University of Oxford, UK.</aff></contrib-group><author-notes><corresp><bold>Correspondence</bold> Dr. Hilkens <email>n.a.hilkens-3@umcutrecht.nl</email></corresp><fn fn-type="financial-disclosure"><p>Go to <ext-link ext-link-type="uri" xlink:href="http://n.neurology.org/lookup/doi/10.1212/WNL.0000000000004997">Neurology.org/N</ext-link> for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.</p></fn><fn fn-type="other"><p>Coinvestigators are listed at <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/WNL/A169">http://links.lww.com/WNL/A169</ext-link>.</p></fn><fn fn-type="other"><p>The Article Processing Charge was funded by Utrecht University.</p></fn></author-notes><pub-date pub-type="ppub"><day>20</day><month>2</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>20</day><month>2</month><year>2018</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="ppub"/>. --><volume>90</volume><issue>8</issue><fpage>e683</fpage><lpage>e689</lpage><history><date date-type="received"><day>07</day><month>7</month><year>2017</year></date><date date-type="accepted"><day>14</day><month>11</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>American Academy of Neurology</copyright-holder><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND)</ext-link>, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="NEUROLOGY2017834184.pdf"/><abstract><sec><title>Objective</title><p>To study the early time course of major bleeding and its subtypes in patients with cerebral ischemia on dual and single antiplatelet therapy.</p></sec><sec><title>Methods</title><p>We performed a post hoc analysis on individual patient data from 6 randomized clinical trials (Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events [CAPRIE], Second European Stroke Prevention Study [ESPS-2], Management of Atherothrombosis With Clopidogrel in High-Risk Patients [MATCH], Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance [CHARISMA], European/Australasian Stroke Prevention in Reversible Ischaemia Trial [ESPRIT], and Prevention Regimen for Effectively Avoiding Second Strokes [PRoFESS]) including 45,195 patients with a TIA or noncardioembolic ischemic stroke. We studied incidence rates of bleeding per antiplatelet regimen stratified by time from randomization (&#x02264;30, 31&#x02013;90, 91&#x02013;180, 181&#x02013;365, &#x0003e;365 days). We calculated incidence rates per trial and pooled estimates with random-effects meta-analysis. We performed Poisson regression to assess differences between time periods with adjustment for age and sex.</p></sec><sec><title>Results</title><p>The incidence of major bleeding on aspirin plus clopidogrel and aspirin plus -dipyridamole was highest in the first 30 days, 5.8 and 4.9 per 100 person-years, respectively, and was significantly higher than at 31 to 90 days (rate ratio 1.98, 95% confidence interval 1.16&#x02013;3.40 for aspirin plus clopidogrel; rate ratio 1.94, 95% confidence interval 1.24&#x02013;3.03 for aspirin plus dipyridamole). Incidence rates on aspirin and clopidogrel monotherapy were 2.8 and 2.5 per 100 person-years, respectively, in the first 30 days, with no significant change over time. The time course was similar for gastrointestinal bleeds. There was no early excess of intracranial hemorrhage in patients on either dual or single antiplatelet therapy.</p></sec><sec><title>Conclusion</title><p>Dual antiplatelet therapy is associated with high early risks of major and gastrointestinal bleeding that decline after the first month in trial cohorts.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta><custom-meta><meta-name>STATUS</meta-name><meta-value>ONLINE-ONLY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Antiplatelet drugs are widely applied in the secondary prevention of cardiovascular disease. Although they successfully reduce the risk of recurrent ischemic events,<sup><xref rid="R1" ref-type="bibr">1</xref></sup> antiplatelet drugs are associated with a small but relevant risk of serious bleeding,<sup><xref rid="R1" ref-type="bibr">1</xref></sup> which is reported to vary between 1%/y and 1.5%/y.<sup><xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R3" ref-type="bibr">3</xref></sup> The prognosis of patients who have experienced a bleeding event is worse, with higher all-cause and cardiovascular mortality.<sup><xref rid="R4" ref-type="bibr">4</xref></sup> Given the wide application of antiplatelet therapy and consequences of bleeding events, it is important to gain more insight into the safety of antiplatelet agents.</p><p>It has been shown previously that the excess risk of major bleeding on aspirin compared with placebo falls with time in primary prevention trials, driven mainly by an excess early risk of bleeding on aspirin.<sup><xref rid="R5" ref-type="bibr">5</xref></sup> It is uncertain whether the time course would be the same in the secondary prevention of cerebral ischemia. In addition, it is unknown whether the time course differs for dual antiplatelet therapy, which is known to be associated with higher risks of bleeding than monotherapy.<sup><xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R7" ref-type="bibr">7</xref></sup> Indeed, there is some preliminary evidence of a high early risk of bleeding on dual antiplatelet treatment after TIA and minor stroke, particularly among aspirin-naive patients,<sup><xref rid="R8" ref-type="bibr">8</xref></sup> but larger studies are required. We aimed to study the time course of major bleeding events and their subtypes in patients with cerebral ischemia on dual and single antiplatelet therapy.</p><sec sec-type="methods" id="s1"><title>Methods</title><sec id="s1-1"><title>Study population</title><p>We analyzed individual patient data from 6 randomized clinical trials (Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events [CAPRIE], Second European Stroke Prevention Study [ESPS-2], Management of Atherothrombosis With Clopidogrel in High-Risk Patients [MATCH], Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance [CHARISMA], European/Australasian Stroke Prevention in Reversible Ischaemia Trial [ESPRIT], and Prevention Regimen for Effectively Avoiding Second Strokes [PRoFESS]<sup><xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R9" ref-type="bibr">9</xref><xref ref-type="bibr" rid="R10">&#x02013;</xref><xref rid="R12" ref-type="bibr">12</xref></sup>) investigating the efficacy of antiplatelet agents in patients with a TIA or ischemic stroke. Details of the individual patient data meta-analysis have been described previously.<sup><xref rid="R13" ref-type="bibr">13</xref></sup> In total, 48,023 patients with cerebral ischemia were included in the trials between 1989 and 2006. Details of the included trials are presented in <xref ref-type="table" rid="T1">table 1</xref>. Aspirin was studied in 4 trials (CAPRIE, ESPS-2, CHARISMA, and ESPRIT), clopidogrel was studied in 3 (CAPRIE, MATCH, and PRoFESS), aspirin in combination with (extended-release) dipyridamole was examined in 3 (ESPS-2, ESPRIT, and PRoFESS), and aspirin in combination with clopidogrel was assessed in 2 (MATCH and CHARISMA). The ESPS-2 trial had 4 arms and randomized patients to aspirin, aspirin plus extended-release dipyridamole, extended-release dipyridamole only, or placebo. Median follow-up ranged from 1.4 to 3.5 years.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Overview of included trials</p></caption><graphic xlink:href="NEUROLOGY2017834184TT1"/></table-wrap><p>We excluded patients with a possible cardioembolic origin of their stroke (those with a history of atrial fibrillation or Trial of ORG 10172 in Acute Stroke Treatment classification of cardioembolic stroke). We used trial-specific definitions for major bleeding. Major bleeding events included bleedings that were fatal, intracranial, or significantly disabling or required hospital admission. Intracranial bleeding events included intracerebral hemorrhages, subarachnoid hemorrhages, and subdural and epidural hematomas. Hemorrhagic transformations of ischemic strokes were not counted as intracranial hemorrhages. Gastrointestinal bleeding events included upper and lower gastrointestinal bleeds that were fatal or required hospital admission.</p></sec><sec id="s1-2"><title>Statistical analysis</title><p>We restricted our analyses to patients who were on treatment. For patients who permanently discontinued trial medication, on-treatment time was defined as time until last intake of study drugs plus 28 days. For patients who completed the trial, on-treatment time was the same as intention-to-treat time. We calculated incidence rates of bleeding per antiplatelet regimen stratified by time from randomization (&#x02264;30, 31&#x02013;90, 91&#x02013;180, 181&#x02013;365, and &#x0003e;365 days). Incidence rates were calculated for each trial separately and were subsequently pooled per antiplatelet regimen with random-effects meta-analysis. We performed Poisson regression analysis to quantify the difference between time periods with adjustment for age and sex. Rate ratios were calculated per trial and subsequently pooled per antiplatelet regimen with random-effects meta-analysis. The time period of 31 to 90 days was chosen as the reference category in all analyses. We examined the influence of age and prior antiplatelet drug use on the time course of bleeding by performing stratified analyses. Definitions of prior antiplatelet drug use varied considerably across trials; therefore, we used prior vascular disease as a proxy for long-term prior antiplatelet drug use, which we defined as a medical history of stroke, TIA, myocardial infarction, angina, or peripheral artery disease. All analyses were performed with R version 3.2.2.</p></sec><sec id="s1-3"><title>Standard protocol approvals, registrations, and patients consents</title><p>The trials were approved by the ethics committee or institutional review board at each participating center, and all patients gave written informed consent.</p></sec></sec><sec sec-type="results" id="s2"><title>Results</title><p>After the exclusion of patients with a possible cardioembolic stroke (n = 1,829) and patients who permanently discontinued treatment but for whom the date of last intake was unknown (n = 999; rate of major bleeding 0.8 per 100 person-years), 45,195 patients remained for the analysis. During 82,199 person-years of follow-up, 1,338 major bleedings, 324 intracranial bleedings, and 618 gastrointestinal bleedings occurred. Baseline characteristics of patients are presented in <xref ref-type="table" rid="T2">table 2</xref>.</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Baseline characteristics of 45,195 patients included in the analyses</p></caption><graphic xlink:href="NEUROLOGY2017834184TT2"/></table-wrap><p>The time course of major bleeding per antiplatelet regimen is displayed in <xref ref-type="fig" rid="F1">figure 1</xref>. The risk of major bleeding was highest during the first 30 days for all antiplatelet regimens except for dipyridamole only. The incidence rate was 2.8 per 100 person-years for aspirin, 2.5 per 100 person-years for clopidogrel, 4.9 per 100 person-years for aspirin plus dipyridamole, and 5.8 per 100 person-years for aspirin plus clopidogrel (figure e-1, <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/WNL/A167">http://links.lww.com/WNL/A167</ext-link>). Results per trial are shown in figures e-2 through e-6. In patients on dual antiplatelet therapy, the risk of major bleeding was significantly higher in the first 30 days compared with 31 to 90 days (rate ratio [RR] 1.98, 95% confidence interval [CI] 1.16&#x02013;3.40 for aspirin plus clopidogrel; RR 1.94, 95% CI 1.24&#x02013;3.03 for aspirin plus dipyridamole, <xref ref-type="table" rid="T3">table 3</xref>). No significant change over time was seen for single antiplatelet regimens (RR 1.27, 95% CI 0.69&#x02013;2.37 for aspirin; RR 1.28, 95% CI 0.66&#x02013;2.48 for clopidogrel; and RR 0.87, 95% CI 0.12&#x02013;4.44 for dipyridamole, <xref ref-type="table" rid="T3">table 3</xref>). The same patterns were seen for gastrointestinal bleeds (<xref ref-type="fig" rid="F2">figure 2A</xref>). Risk of intracranial hemorrhage was stable over time (<xref ref-type="fig" rid="F2">figure 2B</xref> and table e-1, <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/WNL/A168">http://links.lww.com/WNL/A168</ext-link>). Pooled incidence rates of gastrointestinal and intracranial bleeding per antiplatelet regimen are presented in figures e-7 and e-8.</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Time course of major bleeding per antiplatelet regimen (pooled estimates)</title><p>(A) Single antiplatelet therapy (APT), (B) dual APT, and (C) dipyridamole and placebo.</p></caption><graphic xlink:href="NEUROLOGY2017834184FF1"/></fig><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Adjusted rate ratios (95% confidence interval) for major bleeding</p></caption><graphic xlink:href="NEUROLOGY2017834184TT3"/></table-wrap><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Time course of (A) gastrointestinal bleeding and(B) intracranial bleeding per antiplatelet regimen (pooled estimates)</title><p>APT = antiplatelet therapy.</p></caption><graphic xlink:href="NEUROLOGY2017834184FF2"/></fig><p>Among elderly patients (age &#x02265;65 years), absolute risks of major bleeding were higher. The time course of the risk of bleeding was comparable for younger and older patients (figure e-9, <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/WNL/A167">http://links.lww.com/WNL/A167</ext-link>). A total of 17,909 patients (40%) had a diagnosis of vascular disease before their presenting event. Patterns of bleeding risk over time were essentially similar for patients with and without prior vascular disease (figure e-10).</p></sec><sec sec-type="discussion" id="s3"><title>Discussion</title><p>Our study showed high early risks of major bleeding and, more specifically, gastrointestinal bleeding on dual antiplatelet therapy that decline over time. There was no early excess risk of intracranial hemorrhages among patients on either dual antiplatelet therapy or monotherapy.</p><p>Multiple trials have shown the increased risk of major bleeding associated with long-term dual antiplatelet therapy after stroke: MATCH, CHARISMA, and Secondary Prevention of Small Subcortical Strokes Trial (SPS3) demonstrated that aspirin plus clopidogrel is associated with statistically significant higher bleeding risks than either of the regimens separately.<sup><xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R14" ref-type="bibr">14</xref></sup> Furthermore, the PRoFESS trial showed that aspirin plus dipyridamole led to more major and intracranial bleedings than clopidogrel monotherapy.<sup><xref rid="R12" ref-type="bibr">12</xref></sup> Recent trials have investigated the benefit of a short course of aspirin plus clopidogrel, aiming to reduce the risk of early recurrent strokes without exposing patients to long-term dual antiplatelet treatment. Combination therapy was shown to be more protective against ischemic events than monotherapy, but results regarding risk of bleeding in the early phase were conflicting.<sup><xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R16" ref-type="bibr">16</xref></sup> While the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events (CHANCE) trial showed similar risks of bleeding among both groups,<sup><xref rid="R15" ref-type="bibr">15</xref></sup> the Fast Assessment of Stroke and Transient Ischaemic Attack to Prevent Early Recurrence (FASTER) trial showed a significantly higher risk of symptomatic and asymptomatic bleeds among patients treated with dual antiplatelet therapy.<sup><xref rid="R16" ref-type="bibr">16</xref></sup> The recent Triple Antiplatelets for Reducing Dependency in Ischaemic Stroke (TARDIS) trial compared short-term triple therapy (aspirin plus dipyridamole plus clopidogrel) with guideline-based therapy and found no net clinical benefit due to an excess of bleeding complications with triple antiplatelet therapy.<sup><xref rid="R17" ref-type="bibr">17</xref></sup></p><p>Evidence for a time course of bleeding risk is scarce. Post hoc analyses on data from CHARISMA showed that the excess risk of bleeding on aspirin plus clopidogrel was greatest in the first year and similar to aspirin thereafter.<sup><xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R19" ref-type="bibr">19</xref></sup> This is in line with our results indicating high early risks on dual antiplatelet therapy that decline over time. Results from this study and ours suggest that some form of resistance to antiplatelet drugs occurs over time. Previous studies investigating platelet response over time have shown conflicting results. Some reported stable platelet reactivity,<sup><xref rid="R20" ref-type="bibr">20</xref></sup> while others showed decreased platelet inhibition after the first months of exposure to both aspirin and clopidogrel.<sup><xref rid="R21" ref-type="bibr">21</xref><xref ref-type="bibr" rid="R22">&#x02013;</xref><xref rid="R23" ref-type="bibr">23</xref></sup> The mechanisms that cause this reduced sensitivity over time remain unclear. Possibly, upregulation of other pathways that mediate platelet aggregation may play a role. Our findings may also suggest that patients who are prone to bleeding experience a bleed shortly after the start of treatment, leaving a cohort that is at relatively lower risk. Alternatively, the high early risk may be explained partly by the natural history of bleeds as suggested by the time course in placebo-treated patients. However, the number of bleeds in the placebo group was small, and analyses of other data sources are required to better understand the natural history of bleeding after stroke.</p><p>High bleeding risks on aspirin plus clopidogrel have been reported previously and are a cause for concern. A post hoc analysis on data from the Effect of Urgent Treatment of Transient Ischemic Attack and Minor Stroke on early Recurrent Stroke (EXPRESS) study and FASTER pilot trial showed excessive risks during the first 90 days, particularly among aspirin-naive patients.<sup><xref rid="R8" ref-type="bibr">8</xref></sup> Whether the risk decreased over time was not investigated. The high observed risks were attributed partly to the fact that patients were vulnerable shortly after their TIA or ischemic stroke. However, our data show that after the acute phase of TIA or stroke, initiation of dual antiplatelet therapy is accompanied by a doubling of risk in the first 30 days.</p><p>Our study addresses the time course of gastrointestinal and intracranial bleeding separately. The finding that aggressive antiplatelet therapy has a more pronounced effect on gastrointestinal bleeding is plausible because patients with inherited and acquired platelet disorders often present with mucocutaneous bleeding patterns.<sup><xref rid="R24" ref-type="bibr">24</xref></sup></p><p>A strength of our study is the large sample size with a large number of bleeding events. In addition, the quality of the data was high, with regular follow-up and adjudication of events by an independent committee. Furthermore, we were able to restrict our analysis to patients who were on treatment, thereby reducing the possibility that our findings reflect poor compliance. Our study also has limitations. First, we did not have data on other antiplatelet agents such as cilostazol, terutroban, or triflusal. However, the antiplatelet drugs investigated in our study are those recommended as first-line agents in current guidelines.<sup><xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R26" ref-type="bibr">26</xref></sup> Second, absolute risks of bleeding may have been underestimated because patients at highest bleeding risk were excluded from the trials. It is also possible that the time course of bleeding risk might differ in older or frailer populations. Third, control of medication intake was not performed in all trials; therefore, we cannot exclude that patients who were included in the on-treatment analyses in reality did not take their medication anymore. Finally, we performed a post hoc analysis on trial data, and although adjustment for age and sex did not change the results, the possibility of residual confounding remains.</p><p>The risk of major bleeding and, more specifically, gastrointestinal bleeding is increased 2-fold in the first month on dual antiplatelet treatment. The risk of intracranial hemorrhage is stable over time. Although the risk of early recurrent ischemic events will likely outweigh the risk of bleeding, our findings draw attention to the high early risks of bleeding associated with dual antiplatelet therapy, which may have previously been underestimated. The high early risks may warrant the initiation of gastroprotective agents in patients on dual antiplatelet therapy, as well as close monitoring of patients in the early phase.</p></sec></body><back><ack><title>Acknowledgment</title><p>The authors thank the ESPRIT Steering Committee for providing access to the ESPRIT data and Sanofi-Aventis and Bristol-Myers Squibb for giving access to the databases of CAPRIE, MATCH, and CHARISMA. Boehringer Ingelheim Pharmaceuticals, Inc supported this work by providing access to the clinical trial databases of ESPS-2 and PRoFESS.</p></ack><sec sec-type="contributions"><title>Author contributions</title><p content-type="contributions">N.A.H. did the statistical analysis, wrote the first draft of the article, and was supervised by J.P.G., N.A.H., A.A., L.J.K., P.M.R., and J.P.G. made substantial contributions to the conception and design of the study, data analysis, and interpretation of data; they also contributed to drafting of the article and its critical revision for important intellectual content. P.M.B. and L.C. were involved in data collection, interpretation of the data, and revision of the manuscript for important intellectual content. J.P.G. had the final responsibility for the analyses and the content of the article.</p></sec><sec sec-type="funding"><title>Study funding</title><p content-type="funding">Dr. J.P. Greving and Dr N.A. Hilkens are supported by a grant from the Dutch Heart Foundation (grant 2013T128). Dr. Greving is also supported by a VENI grant from the Netherlands Organization for Health Research and Development (ZonMw), grant 916.11.129.</p></sec><sec sec-type="disclosure"><title>Disclosure</title><p content-type="disclosure">The authors report no disclosures relevant to the manuscript. Go to <ext-link ext-link-type="uri" xlink:href="http://n.neurology.org/lookup/doi/10.1212/WNL.0000000000004997">Neurology.org/N</ext-link> for full disclosures.</p></sec><glossary><title>Glossary</title><def-list><def-item><term id="G1">CAPRIE</term><def><p>Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events</p></def></def-item><def-item><term id="G2">CHANCE</term><def><p>Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events</p></def></def-item><def-item><term id="G3">CHARISMA</term><def><p>Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance</p></def></def-item><def-item><term id="G4">CI</term><def><p>confidence interval</p></def></def-item><def-item><term id="G5">ESPRIT</term><def><p>European/Australasian Stroke Prevention in Reversible Ischaemia Trial</p></def></def-item><def-item><term id="G6">ESPS-2</term><def><p>Second European Stroke Prevention Study</p></def></def-item><def-item><term id="G7">EXPRESS</term><def><p>Effect of Urgent Treatment of Transient Ischemic Attack and Minor Stroke on early Recurrent Stroke</p></def></def-item><def-item><term id="G8">FASTER</term><def><p>Fast Assessment of Stroke and Transient Ischaemic Attack to Prevent Early Recurrence</p></def></def-item><def-item><term id="G9">MATCH</term><def><p>Management of Atherothrombosis With Clopidogrel in High-Risk Patients</p></def></def-item><def-item><term id="G10">PRoFESS</term><def><p>Prevention Regimen for Effectively Avoiding Second Strokes</p></def></def-item><def-item><term id="G11">RR</term><def><p>rate ratio</p></def></def-item><def-item><term id="G12">SPS3</term><def><p>Secondary Prevention of Small Subcortical Strokes Trial</p></def></def-item><def-item><term id="G13">TARDIS</term><def><p>Triple Antiplatelets for Reducing Dependency in Ischaemic Stroke</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><collab>Antithrombotic Trialists' (ATT) Collaboration</collab>, <person-group person-group-type="author"><name name-style="western"><surname>Baigent</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Blackwell</surname><given-names>L</given-names></name>, <etal>et al</etal></person-group>
<article-title>Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials</article-title>. <source>Lancet</source>
<year>2009</year>;<volume>373</volume>:<fpage>1849</fpage>&#x02013;<lpage>1860</lpage>.<pub-id pub-id-type="pmid">19482214</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Geraghty</surname><given-names>OC</given-names></name>, <name name-style="western"><surname>Mehta</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Rothwell</surname><given-names>PM</given-names></name></person-group>; <collab>Oxford Vascular Study</collab>. <article-title>Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study</article-title>. <source>Lancet</source>
<year>2017</year>;<volume>390</volume>:<fpage>490</fpage>&#x02013;<lpage>499</lpage>.<pub-id pub-id-type="pmid">28622955</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alberts</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Bhatt</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>SC</given-names><suffix>Jr</suffix></name>, <etal>et al</etal></person-group>
<article-title>Risk factors and outcomes for patients with vascular disease and serious bleeding events</article-title>. <source>Heart</source>
<year>2011</year>;<volume>97</volume>:<fpage>1507</fpage>&#x02013;<lpage>1512</lpage>.<pub-id pub-id-type="pmid">21715441</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berger</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Bhatt</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Steg</surname><given-names>PG</given-names></name>, <etal>et al</etal></person-group>
<article-title>Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial</article-title>. <source>Am Heart J</source>
<year>2011</year>;<volume>162</volume>:<fpage>98</fpage>&#x02013;<lpage>105.e1</lpage>.<pub-id pub-id-type="pmid">21742095</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rothwell</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Price</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Fowkes</surname><given-names>FG</given-names></name>, <etal>et al</etal></person-group>
<article-title>Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials</article-title>. <source>Lancet</source>
<year>2012</year>;<volume>379</volume>:<fpage>1602</fpage>&#x02013;<lpage>1612</lpage>.<pub-id pub-id-type="pmid">22440946</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhatt</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Fox</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Hacke</surname><given-names>W</given-names></name>, <etal>et al</etal></person-group>
<article-title>Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events</article-title>. <source>N Engl J Med</source>
<year>2006</year>;<volume>354</volume>:<fpage>1706</fpage>&#x02013;<lpage>1717</lpage>.<pub-id pub-id-type="pmid">16531616</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diener</surname><given-names>HC</given-names></name>, <name name-style="western"><surname>Bogousslavsky</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Brass</surname><given-names>LM</given-names></name>, <etal>et al</etal></person-group>
<article-title>Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial</article-title>. <source>Lancet</source>
<year>2004</year>;<volume>364</volume>:<fpage>331</fpage>&#x02013;<lpage>337</lpage>.<pub-id pub-id-type="pmid">15276392</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geraghty</surname><given-names>OC</given-names></name>, <name name-style="western"><surname>Kennedy</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Chandratheva</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Marquardt</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Buchan</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Rothwell</surname><given-names>PM</given-names></name></person-group>
<article-title>Preliminary evidence of a high risk of bleeding on aspirin plus clopidogrel in aspirin-naive patients in the acute phase after TIA or minor ischaemic stroke</article-title>. <source>Cerebrovasc Dis</source>
<year>2010</year>;<volume>29</volume>:<fpage>460</fpage>&#x02013;<lpage>467</lpage>.<pub-id pub-id-type="pmid">20299785</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><collab>CAPRIE Steering Committee</collab>. <article-title>A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE): CAPRIE Steering Committee</article-title>. <source>Lancet</source>
<year>1996</year>;<volume>348</volume>:<fpage>1329</fpage>&#x02013;<lpage>1339</lpage>.<pub-id pub-id-type="pmid">8918275</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diener</surname><given-names>HC</given-names></name>, <name name-style="western"><surname>Cunha</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Forbes</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Sivenius</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Smets</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Lowenthal</surname><given-names>A</given-names></name></person-group>
<article-title>European Stroke Prevention Study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke</article-title>. <source>J Neurol Sci</source>
<year>1996</year>;<volume>143</volume>:<fpage>1</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="pmid">8981292</pub-id></mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><collab>ESPRIT Study Group</collab>, <person-group person-group-type="author"><name name-style="western"><surname>Halkes</surname><given-names>PH</given-names></name>, <name name-style="western"><surname>van Gijn</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Kappelle</surname><given-names>LJ</given-names></name>, <name name-style="western"><surname>Koudstaal</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Algra</surname><given-names>A</given-names></name></person-group>
<article-title>Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial</article-title>. <source>Lancet</source>
<year>2006</year>;<volume>367</volume>:<fpage>1665</fpage>&#x02013;<lpage>1673</lpage>.<pub-id pub-id-type="pmid">16714187</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sacco</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>Diener</surname><given-names>HC</given-names></name>, <name name-style="western"><surname>Yusuf</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>
<article-title>Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke</article-title>. <source>N Engl J Med</source>
<year>2008</year>;<volume>359</volume>:<fpage>1238</fpage>&#x02013;<lpage>1251</lpage>.<pub-id pub-id-type="pmid">18753638</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greving</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Diener</surname><given-names>HC</given-names></name>, <name name-style="western"><surname>Csiba</surname><given-names>L</given-names></name>, <etal>et al</etal></person-group>
<article-title>Individual patient data meta-analysis of antiplatelet regimens after noncardioembolic stroke or TIA: rationale and design</article-title>. <source>Int J Stroke</source>
<year>2015</year>;<volume>10</volume>(<issue>suppl A100</issue>):<fpage>145</fpage>&#x02013;<lpage>150</lpage>.<pub-id pub-id-type="pmid">26282569</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><collab>SPS3 Investigators</collab>, <person-group person-group-type="author"><name name-style="western"><surname>Benavente</surname><given-names>OR</given-names></name>, <name name-style="western"><surname>Hart</surname><given-names>RG</given-names></name>, <etal>et al</etal></person-group>
<article-title>Effects of clopidogrel added to aspirin in patients with recent lacunar stroke</article-title>. <source>N Engl J Med</source>
<year>2012</year>;<volume>367</volume>:<fpage>817</fpage>&#x02013;<lpage>825</lpage>.<pub-id pub-id-type="pmid">22931315</pub-id></mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name>, <etal>et al</etal></person-group>
<article-title>Clopidogrel with aspirin in acute minor stroke or transient ischemic attack</article-title>. <source>N Engl J Med</source>
<year>2013</year>;<volume>369</volume>:<fpage>11</fpage>&#x02013;<lpage>19</lpage>.<pub-id pub-id-type="pmid">23803136</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kennedy</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hill</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Ryckborst</surname><given-names>KJ</given-names></name>, <etal>et al</etal></person-group>
<article-title>Fast Assessment of Stroke and Transient Ischaemic Attack to Prevent Early Recurrence (FASTER): a randomised controlled pilot trial</article-title>. <source>Lancet Neurol</source>
<year>2007</year>;<volume>6</volume>:<fpage>961</fpage>&#x02013;<lpage>969</lpage>.<pub-id pub-id-type="pmid">17931979</pub-id></mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Bath</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Woodhouse</surname><given-names>LJ</given-names></name>, <name name-style="western"><surname>Flaherty</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Havard</surname><given-names>D</given-names></name>, <name name-style="western"><surname>England</surname><given-names>TJ</given-names></name>, <name name-style="western"><surname>Sprigg</surname><given-names>N</given-names></name></person-group>
<source>Intensive versus guideline antiplatelet therapy for preventing recurrence in patients with acute ischaemic stroke or TIA: main results from the Triple Antiplatelets for Reducing Dependency in Ischaemic Stroke (TARDIS) Trial</source>. Presented at the 2017 International Stroke Conference; February 22&#x02013;24, 2017; Houston, TX.</mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berger</surname><given-names>PB</given-names></name>, <name name-style="western"><surname>Bhatt</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Fuster</surname><given-names>V</given-names></name>, <etal>et al</etal></person-group>
<article-title>Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial</article-title>. <source>Circulation</source>
<year>2010</year>;<volume>121</volume>:<fpage>2575</fpage>&#x02013;<lpage>2583</lpage>.<pub-id pub-id-type="pmid">20516378</pub-id></mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhatt</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Flather</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Hacke</surname><given-names>W</given-names></name>, <etal>et al</etal></person-group>
<article-title>Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial</article-title>. <source>J Am Coll Cardiol</source>
<year>2007</year>;<volume>49</volume>:<fpage>1982</fpage>&#x02013;<lpage>1988</lpage>.<pub-id pub-id-type="pmid">17498584</pub-id></mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saw</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Madsen</surname><given-names>EH</given-names></name>, <name name-style="western"><surname>Chan</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Maurer-Spurej</surname><given-names>E</given-names></name></person-group>
<article-title>The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) study</article-title>. <source>J Am Coll Cardiol</source>
<year>2008</year>;<volume>52</volume>:<fpage>1826</fpage>&#x02013;<lpage>1833</lpage>.<pub-id pub-id-type="pmid">19038679</pub-id></mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Helgason</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Bolin</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Hoff</surname><given-names>JA</given-names></name>, <etal>et al</etal></person-group>
<article-title>Development of aspirin resistance in persons with previous ischemic stroke</article-title>. <source>Stroke</source>
<year>1994</year>;<volume>25</volume>:<fpage>2331</fpage>&#x02013;<lpage>2336</lpage>.<pub-id pub-id-type="pmid">7974569</pub-id></mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nuhrenberg</surname><given-names>TG</given-names></name>, <name name-style="western"><surname>Stratz</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Leggewie</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>
<article-title>Temporal variability in the antiplatelet effects of clopidogrel and aspirin after elective drug-eluting stent implantation: an ADAPT-DES substudy</article-title>. <source>Thromb Haemost</source>
<year>2015</year>;<volume>114</volume>:<fpage>1020</fpage>&#x02013;<lpage>1027</lpage>.<pub-id pub-id-type="pmid">26305340</pub-id></mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pulcinelli</surname><given-names>FM</given-names></name>, <name name-style="western"><surname>Pignatelli</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Celestini</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Riondino</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Gazzaniga</surname><given-names>PP</given-names></name>, <name name-style="western"><surname>Violi</surname><given-names>F</given-names></name></person-group>
<article-title>Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients</article-title>. <source>J Am Coll Cardiol</source>
<year>2004</year>;<volume>43</volume>:<fpage>979</fpage>&#x02013;<lpage>984</lpage>.<pub-id pub-id-type="pmid">15028353</pub-id></mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hassan</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Kroll</surname><given-names>MH</given-names></name></person-group>
<article-title>Acquired disorders of platelet function</article-title>. <source>Hematology Am Soc Hematol Educ Program</source>
<year>2005</year>:<fpage>403</fpage>&#x02013;<lpage>408</lpage>.<pub-id pub-id-type="pmid">16304411</pub-id></mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kernan</surname><given-names>WN</given-names></name>, <name name-style="western"><surname>Ovbiagele</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Black</surname><given-names>HR</given-names></name>, <etal>et al</etal></person-group>
<article-title>Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association</article-title>. <source>Stroke</source>
<year>2014</year>;<volume>45</volume>:<fpage>2160</fpage>&#x02013;<lpage>2236</lpage>.<pub-id pub-id-type="pmid">24788967</pub-id></mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal"><collab>European Stroke Organisation (ESO) Executive Committee, ESO Writing Committee</collab>. <article-title>Guidelines for management of ischaemic stroke and transient ischaemic attack 2008</article-title>. <source>Cerebrovasc Dis</source>
<year>2008</year>;<volume>25</volume>:<fpage>457</fpage>&#x02013;<lpage>507</lpage>.<pub-id pub-id-type="pmid">18477843</pub-id></mixed-citation></ref></ref-list></back></article>